Granzyme B

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
Freitag, April 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

OncoOne Presents Preclinical Data Update from oxMIF-targeting Pipeline at the 2023 AACR Annual Meeting

Retrieved on: 
Freitag, April 14, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Pancreatic cancer, Radiation, AACR, Molecule, CRC, Doctor of Philosophy, Granzyme, CD16, Macrophage, Cancer, Coronavirus Scientific Advisory Board, Granzyme B, Tumor microenvironment, NK, Assistant, LAMP1, Harvard Medical School, HSG, American Association for Cancer Research, Patient, Colorectal cancer, Annual general meeting, TME, Neoplasm, Poster, Natural killer T cell, Vaccine, Pharmaceutical industry

Alexander Schinagl, Ph.D., CTO of OncoOne added: “We are pleased to see that our PreTarg-it® program, ON-05, demonstrated such promising initial preclinical results including significant tumor regression.

Key Points: 
  • Alexander Schinagl, Ph.D., CTO of OncoOne added: “We are pleased to see that our PreTarg-it® program, ON-05, demonstrated such promising initial preclinical results including significant tumor regression.
  • The data build on and strengthen the excellent tumor penetration, tumor retention and reduced tumor proliferation preclinical data shown in previously analyzed mouse models.
  • These preclinical data highlight the potential of ON203 to significantly modulate the TME towards immune-stimulating functions in tumor material collected from patients.
  • Both posters will be available on OncoOne’s website upon conclusion of the AACR 2023 Annual Meeting.